Edition:
United States

Marinus Pharmaceuticals Inc (MRNS.OQ)

MRNS.OQ on NASDAQ Stock Exchange Global Market

7.37USD
1:44pm EST
Change (% chg)

$-0.52 (-6.59%)
Prev Close
$7.89
Open
$8.18
Day's High
$8.18
Day's Low
$7.31
Volume
269,624
Avg. Vol
402,492
52-wk High
$9.86
52-wk Low
$0.83

Chart for

About

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral... (more)

Overall

Beta: 2.48
Market Cap(Mil.): $318.99
Shares Outstanding(Mil.): 40.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Marinus Pharmaceuticals files for mixed shelf of up to $200 mln

* Marinus Pharmaceuticals Inc - files for a mixed shelf of up to $200 million - SEC filing‍​ Source text: [http://bit.ly/2z23P1a] Further company coverage:

Oct 31 2017

BRIEF-Marinus Pharmaceuticals qtrly loss per share $0.15‍​

* Marinus Pharmaceuticals provides business update and reports third quarter 2017 financial results

Oct 31 2017

BRIEF-Bain Capital Life Sciences Fund reports 14.4 pct passive stake in Marinus Pharmaceuticals

* Bain Capital Life Sciences Fund L.P reports 14.4 percent passive stake in Marinus Pharmaceuticals Inc as of Sept 19, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2fUP6u2) Further company coverage:

Sep 28 2017

BRIEF-Marinus Pharmaceuticals announces pricing of public offering of common stock

* Marinus Pharmaceuticals announces pricing of public offering of common stock

Sep 15 2017

BRIEF-Marinus Pharmaceuticals announces public offering of common stock

* Marinus Pharmaceuticals Inc announces public offering of common stock

Sep 14 2017

BRIEF-Marinus announces successful clinical trial results

* Marinus announces successful clinical trial results and declares CDKL5 disorder its lead pediatric orphan epilepsy program for ganaxolone

Sep 11 2017

BRIEF-EecoR1 Capital reports 12.2 pct passive stake in Marinus Pharmaceuticals

* EecoR1 Capital LLC​ report a 12.2 percent passive stake in Marinus Pharmaceuticals Inc as of August 4, 2017 - SEC filing Source text: (http://bit.ly/2vMhmJe) Further company coverage:

Aug 08 2017

BRIEF-Marinus Pharmaceuticals posts quarterly loss of $0.21 per share

* Provides business update and reports second quarter 2017 financial results

Aug 01 2017

BRIEF-Marinus Pharmaceuticals says Granite Point reports a 9.75 percent passive stake in Marinus- SEC Filing

* Granite point capital management lp reports a 9.75 percent passive stake in marinus pharmaceuticals inc as of july 6, 2017 - sec filing Source text for Eikon: Further company coverage:

Jul 18 2017

BRIEF-Marinus Pharmaceuticals says James Flynn reports 9.98 percent passive stake in Marinus as of July 14, 2017 - sec filing

* James E. Flynn reports a 9.98 percent passive stake in Marinus Pharmaceuticals Inc as of July 14, 2017 - Sec Filing Source text for Eikon: Further company coverage:

Jul 17 2017

Earnings vs. Estimates